United States Patent 12,128,021 (Gamma-Hydroxybutyrate) Scope, Claim Map, and US Patent Landscape
Executive summary: US Patent 12,128,021 is directed to a clinical titration regimen for oral sodium oxybate (gamma-hydroxybutyrate, GHB prodrug/active salt exposure) using a once-per-night dosing schedule with a 4.5 g night-1 initiation into a 1.5 g-per-night increment up-titration, including mandatory stabilization intervals before further increases, with ceasing further up-titration upon therapeutic effect (claimed cap at up to 9 g once per night). The claim set is method-of-treatment focused and is likely to be enforced against prescribers and branded/authorized distribution entities through labeling, prescribing instructions, clinical protocols, and provider “step therapy” pathways, rather than formulation manufacturing alone.
What does US Patent 12,128,021 claim for sodium oxybate once-per-night titration?
Core claim theme (independent claim 1): A method of treating a disorder treatable with gamma-hydroxybutyrate in a human subject, comprising:
- Initiation: dose a pharmaceutical formulation equivalent to 4.5 g sodium oxybate once per night orally.
- Formulation architecture: the formulation has an immediate-release (IR) portion and modified-release (MR) portion.
- Up-titration rule: increase the once-per-night dosage by 1.5 g sodium oxybate.
- Timing constraint: after an up-titrated dose is reached, maintain for at least one week before any further increase.
- Endpoint rule: cease further up-titration upon effect.
- Range variants in dependent claims: once nightly effective range 6 g to 9 g and specific endpoints 6 g / 7.5 g / 9 g.
- Safety/ceiling language: doses higher than 9 g per night are not to be administered (claim 13).
Independent claim 14 is similar but with a somewhat different structural requirement: it emphasizes up-titration in increments and weekly maintenance, without the explicit “ceasing upon effect” language in the independent set as written (though the family includes endpoint/ceasing variations elsewhere).
Independent claim set is not about:
- developing an IR/MR dosage form per se,
- manufacturing steps, or
- a new chemical entity.
It is about a specific clinical dosing protocol for sodium oxybate exposure from an IR/MR product.
How the claims segment dosing protocol into enforceable “steps”
The enforcement leverage in the claims comes from discrete protocol elements that are easy to map to:
- clinical titration instructions,
- prescriber workflows,
- and label-like dosing algorithms.
Key protocol constraints in the claims:
- Nightly dosing frequency: “once per night.”
- Starting dose: “equivalent to 4.5 g.”
- Increment size: “equivalent to 1.5 g.”
- Stabilization interval: “at least one week” (with dependent forms specifying “at least two weeks”).
- Titration progression: multiple dependent schedules spanning weeks 2–3, 4–8, 9–13.
- Endpoint stabilization: maintain stable effective dose after reaching therapeutic target (6 g / 7.5 g / 9 g).
- Cease condition: cease further up-titration upon effect (claim 1).
- Ceiling: “higher than 9 g per night are not to be administered” (claim 13).
Claim-by-claim scope of US 12,128,021: what is covered vs. what is left open
Below is a structured scope view from the claim language you provided.
Independent Claim 1: “cease upon effect” + ≥1-week maintenance
- Initiate 4.5 g once nightly with IR + MR.
- Up-titrate by 1.5 g per nightly step.
- Maintain the up-titrated dose for at least one week.
- Stop titration once effect occurs.
- Dependent claims narrow:
- effective range 6–9 g (claim 2),
- specific endpoints 6 / 7.5 / 9 g (claims 3–5),
- extended stabilization ≥2 weeks (claim 6),
- a specific schedule mapping week ranges 1 through 13 (claims 7–9),
- stable-maintenance after reaching 6/7.5/9 g (claim 10),
- “no change once 9 g reached” (claim 11),
- stimulant co-administration is allowed (claim 12),
- ceiling at ≤9 g (claim 13).
What claim 1 is likely to require for infringement: a single treatment course that matches the initiation dose, increment size, stabilization timing, and cessation logic, plus the use of an oral IR/MR sodium oxybate formulation.
What claim 1 does not require (as written):
- a minimum total titration duration (it requires stabilization at each step but not a total time threshold unless dependent claims apply).
- a particular disorder identity beyond being “treatable with gamma-hydroxybutyrate.”
Independent Claim 14: weekly titration maintaining each up-titrated dose
Claim 14 recasts the protocol:
- Initiate at 4.5 g once nightly IR/MR.
- Up-titrate to effect in increments of 1.5 g per night.
- Maintain each up-titrated dose for at least one week before further increases.
Dependent claims 15–17 lock the effective endpoint at 6 / 7.5 / 9 g.
Dependent claims 18–19 add titration duration requirements (“at least three weeks” / “at least five weeks”).
Claims 20–22 specify a week-by-week maintenance and escalation pathway:
- Week 1: 4.5 g
- Then 6 g at least weeks 2–3
- Then 7.5 g at least weeks 4–8
- Then 9 g at least weeks 9–13
Independent Claim 23: weekly intervals for at least one week
Claim 23 specifies the titration rhythm differently:
- Initiate 4.5 g once nightly with IR/MR.
- Up-titrate in 1.5 g increments at weekly intervals for at least one week.
Dependent claims:
- effective range 6–9 g (claim 24),
- titration period eight weeks (claim 25),
- stable maintenance after up-titration at 6/7.5/9 g (claim 26).
Functional implication: claim 23 is narrower on timing (weekly intervals), but independent 1/14 cover broader “maintain at least one week” patterns, which can still be read to capture weekly interval titration if the regimen conforms.
How strong is the patent estate around this dosing regimen, given the IR/MR sodium oxybate context?
Immediate takeaway: the claim language’s dependence on “IR portion and MR portion” meaningfully narrows the covered embodiments to extended/modified-release sodium oxybate products with an IR+MR architecture. That structure ties the dosing protocol to a particular class of approved products (in the US, the best-known IR/MR sodium oxybate product historically has been sodium oxybate with IR/MR delivery).
Why the IR/MR limitation matters for claim strength
- If a competitor uses a different delivery architecture (pure IR, different release profile, or a different prodrug/form), the “IR + MR portion” limitation becomes an obvious non-infringement lever.
- If a competitor uses an IR/MR product but changes titration rules (increment size, maintenance interval, starting dose), those changes can defeat infringement.
Why the protocol timing constraints are enforceable “hard edges”
Court and jury analysis commonly treats protocol elements like:
- starting dose,
- increment size,
- stabilization interval,
- endpoint/titration stop rules,
as objective regimen descriptors, which can be evidenced by:
- labeling,
- prescribing instructions,
- clinical trial protocols,
- and pharmacy record histories.
What is the likely US patent landscape around sodium oxybate dosing regimens (IR/MR once nightly up-titration)?
Landscape structure: three typical patent buckets
- Product/Constitution patents
Cover the IR/MR sodium oxybate formulation structure, dosing unit design, and potentially manufacturing.
- Method-of-use patents
Cover treatment regimens: titration schedules, step-up rules, discontinuation/ceasing criteria, dose ceilings.
- Patient management and co-therapy patents
Cover stimulant co-administration, monitoring, or behavioral protocols tied to sodium oxybate treatment.
US 12,128,021 is in bucket (2), with a product architecture anchor via “IR portion and MR portion.”
Competitive risk profile created by this claim language
- A generic or alternative manufacturer that launches an IR/MR sodium oxybate product can still face method-of-treatment liability if its product’s commercialization, labeling, or supported prescribing practices track these exact titration steps.
- Conversely, competitors can reduce litigation risk by changing:
- starting dose,
- increment size,
- maintenance interval,
- titration cadence,
- or endpoint logic (including ceasing rules).
When does the patent lose exclusivity? What expiration date should be modeled?
No answer provided. The expiration/timeline cannot be computed from the claim text alone. Patent term and maintenance status require bibliographic data (filing date, priority chain, USPTO status, PTA/PTE, and maintenance fee history), which is not present in the provided material.
What patents protect the same subject matter in the US besides 12,128,021?
No answer provided. A proper landscape requires citation data, related application families, INPADOC/USPTO continuations, and Orange Book listing crosswalks. None of that bibliographic/patent-number data is included beyond the claims.
What formulations are protected: does the patent cover any IR/MR sodium oxybate or a specific release profile?
Direct answer from claim scope: the claims cover a pharmaceutical formulation that has:
- an immediate-release portion, and
- a modified-release portion.
But the claims do not specify:
- the fraction split (IR vs MR),
- particle size, excipient sets, tablet composition,
- specific pharmacokinetic targets,
- or dissolution curves.
That means the formulation scope is limited by the IR/MR structural requirement but not by detailed product parameters in the provided claim text.
Practical inference for freedom-to-operate: an IR/MR sodium oxybate product that uses an equivalent nightly dosing unit and supports titration in 4.5 g then 1.5 g increments with ≥1-week maintenance fits the core regimen elements. Any deviation in delivery architecture could avoid the “IR portion and MR portion” limitation.
How do claims 1, 14, and 23 compare for infringement risk?
Key differences
- Claim 1: includes explicit “ceasing any further up-titrating upon effect.” It also allows a broader pattern because it requires maintaining each up-titrated dose for at least one week.
- Claim 14: frames titration “to effect in increments” and requires maintaining each up-titrated dose for at least one week before further up-titrating. It does not repeat the explicit “cease upon effect” phrasing in the independent statement (though it still culminates in “to effect”).
- Claim 23: specifies titration “in increments … at weekly intervals for at least one week,” which is narrower on timing mechanism.
Risk allocation
A regimen that matches claim 20–22 schedule (week 1 4.5 g; then 6 g for weeks 2–3; then 7.5 g for weeks 4–8; then 9 g for weeks 9–13) will likely read onto:
- claim 14 dependent constructs, and
- claim 1 through dependent mapping, depending on how “ceasing upon effect” is implemented operationally in the regimen.
A regimen that ends earlier (stop before reaching 9 g due to effect) still can infringe claim 1 if effect triggers the cessation after the appropriate up-titration steps.
Does US 12,128,021 cover co-administration with stimulants or patient subsets?
Yes, via claim 12. It includes:
- “further comprising administering a stimulant to the human patient.”
Scope impact: the claim does not limit stimulant class, so the covered field can be broad if the clinical regimen uses stimulants alongside sodium oxybate therapy. The dependence is optional, so infringement can still occur without stimulants if the claim set element is not required by the asserted claim.
What are the generic entry risks for an approved IR/MR sodium oxybate product under this patent?
Given the claim is a method-of-treatment with specific titration instructions, the major risk vectors are:
- Label alignment risk: if generic product labeling or FDA-approved prescribing information includes the same titration schedule, it increases odds of method-of-treatment infringement exposure.
- Provider practice risk: even without identical label language, if clinical practice reliably follows the same titration algorithm, method liability can still be asserted.
- Launch timing risk: if the patent is still in force, Paragraph IV challenges and “carve-out” label strategies become relevant, but exact challenge/settlement status cannot be determined from the provided text.
No question-specific litigation facts (Paragraph IV filings, settlements, injunctions) are provided here; no litigation status can be stated.
Key Takeaways
- US 12,128,021 claims a once-nightly oral sodium oxybate IR/MR titration regimen starting at 4.5 g, stepping by 1.5 g, with mandatory stabilization for at least one week (and sometimes at least two weeks), and using ceasing upon effect language in claim 1.
- The claim family hard-codes common effective endpoints at 6 g, 7.5 g, and 9 g once per night, including a detailed weeks 1–13 progression in dependent claims.
- The IR + MR formulation requirement narrows the covered product architecture to IR/MR sodium oxybate systems.
- Enforceability leverage is driven by objective dosing-step elements (starting dose, increment size, timing, endpoint/cease rules).
- Patent term, exclusivity loss date, Orange Book status, other family members, and litigation/Paragraph IV events are not determinable from the claim text alone.
FAQs
-
Does US 12,128,021 require reaching 9 g to infringe?
No. Claim 1 covers “cease upon effect,” and dependent claims cover effective ranges and specific endpoints, but claim 1’s cessation logic can accommodate earlier cessation.
-
Is weekly titration cadence mandatory under all claims?
No. Claim 23 is explicit about weekly intervals; claims 1 and 14 require at least one week maintenance before further increase, which can be compatible with weekly cadence but is not phrased identically.
-
What happens if a regimen uses a different increment size than 1.5 g?
The increment size is a claim element (“in an amount equivalent to 1.5 g”), so deviation would typically avoid literal infringement.
-
Can the regimen include stimulants and still fall within the claims?
Yes. Claim 12 expressly allows administering a stimulant as an additional step.
-
Does the patent cover only sodium oxybate or any gamma-hydroxybutyrate therapy?
The claims are framed around treating a disorder “treatable with gamma-hydroxybutyrate” but specify the dosing amounts “equivalent to … sodium oxybate,” with an IR/MR oral formulation requirement.
